A carregar...
BRAF kinase inhibitor exerts anti-tumor activity against breast cancer cells via inhibition of FGFR2
Most anti-angiogenic therapies currently being evaluated in clinical trials targetvascular endothelial growth factor (VEGF) pathway; however, the tumor vasculature can acquire resistance to VEGF-targeted therapy by shifting to other angiogenesis mechanisms. Therefore, other potential therapeutic age...
Na minha lista:
| Publicado no: | Am J Cancer Res |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
e-Century Publishing Corporation
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4889718/ https://ncbi.nlm.nih.gov/pubmed/27293997 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|